JP2005505579A - アンタゴニスト - Google Patents

アンタゴニスト Download PDF

Info

Publication number
JP2005505579A
JP2005505579A JP2003530818A JP2003530818A JP2005505579A JP 2005505579 A JP2005505579 A JP 2005505579A JP 2003530818 A JP2003530818 A JP 2003530818A JP 2003530818 A JP2003530818 A JP 2003530818A JP 2005505579 A JP2005505579 A JP 2005505579A
Authority
JP
Japan
Prior art keywords
insulin
seq
growth factor
amino acid
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505579A5 (enExample
Inventor
レヌーカ ピルートラ，
オルガ デドヴァ，
アーサー， ジェイ． ブルーム，
ニール， アイ． ゴールドスタイン，
レニー ブリセット，
ピンガー ワン，
ハオ リュー，
クー−チュアン シャオ，
マイケル レニック，
ポール フレッチャー，
Original Assignee
ノボ・ノルデイスク・エー／エス
ディージーアイ バイオテクノロジーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボ・ノルデイスク・エー／エス, ディージーアイ バイオテクノロジーズ filed Critical ノボ・ノルデイスク・エー／エス
Publication of JP2005505579A publication Critical patent/JP2005505579A/ja
Publication of JP2005505579A5 publication Critical patent/JP2005505579A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2003530818A 2001-09-24 2002-09-24 アンタゴニスト Pending JP2005505579A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/962,756 US6875741B2 (en) 1998-09-02 2001-09-24 Insulin and IGF-1 receptor agonists and antagonists
PCT/US2002/030412 WO2003027246A2 (en) 2001-09-24 2002-09-24 Antagonists

Publications (2)

Publication Number Publication Date
JP2005505579A true JP2005505579A (ja) 2005-02-24
JP2005505579A5 JP2005505579A5 (enExample) 2006-01-05

Family

ID=25506313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003530818A Pending JP2005505579A (ja) 2001-09-24 2002-09-24 アンタゴニスト
JP2003569654A Pending JP2005517741A (ja) 2001-09-24 2002-09-24 インシュリン及びｉｇｆ−１レセプターのアゴニスト及びアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003569654A Pending JP2005517741A (ja) 2001-09-24 2002-09-24 インシュリン及びｉｇｆ−１レセプターのアゴニスト及びアンタゴニスト

Country Status (6)

Country Link
US (1) US6875741B2 (enExample)
EP (2) EP1496935A4 (enExample)
JP (2) JP2005505579A (enExample)
AU (2) AU2002341834A1 (enExample)
CA (2) CA2460055A1 (enExample)
WO (2) WO2003070747A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501664A (ja) * 2015-10-23 2019-01-24 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6521738B2 (en) * 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US20070105778A1 (en) 2002-01-23 2007-05-10 El-Gewely Mohamed R Methods of screening molecular libraries and active molecules identified thereby
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
CA2483330C (en) * 2002-04-22 2013-09-03 Greenville Hospital System Multimeric ligands with enhanced stability
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
AU2003278212B2 (en) * 2002-07-31 2009-07-09 Centre National De La Recherche Scientifique Stem cells derived from adipous tissue and differentiated cells derived from said cells
AU2003275240A1 (en) * 2002-09-24 2004-04-23 Massachusetts Institute Of Technology Methods and compositions for soluble cpg15
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US20050187175A1 (en) * 2003-09-30 2005-08-25 Elly Nedivi Methods and compositions for CPG15-2
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1737493B1 (en) 2004-02-25 2011-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor -1 for inhibiting tumor cell growth
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
ATE461708T1 (de) 2004-05-07 2010-04-15 Univ North Carolina Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
US20100298213A1 (en) * 2004-08-20 2010-11-25 Novo Nordisk A/S Pharmaceutically Active Insulin Receptor-Modulating Molecules
WO2006052468A2 (en) * 2004-10-27 2006-05-18 University Of Denver Adrenocorticotropic hormone analogs and related methods
US20090197800A1 (en) * 2004-10-27 2009-08-06 Novo Nordisk A/S Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
MX2007006640A (es) * 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
PT2100618E (pt) 2005-06-17 2014-04-07 Philadelphia Health & Educatio Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
WO2007011610A2 (en) 2005-07-18 2007-01-25 Acologix, Inc. Protein formulation for promoting hard tissue formation
JP2009511446A (ja) * 2005-10-05 2009-03-19 ノボ・ノルデイスク・エー／エス インスリンレセプターアンタゴニストと、関連した組成物、使用及び方法
AU2007212447B2 (en) * 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
WO2007095113A2 (en) * 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
EP2468767B1 (en) 2006-06-22 2015-10-28 Walter and Eliza Hall Institute of Medical Research Structure of the insulin receptor ectodomain
EP2044246A4 (en) * 2006-07-06 2009-12-16 Molecular Logix Inc LIGAND DRUG DISCOVERY SYSTEM DOMINANT NEGATIVE
EP2152742B1 (en) 2007-04-24 2013-01-23 Antyra, Inc. IGF-1R binding proteins and antagonists
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
SG189769A1 (en) 2008-01-03 2013-05-31 Scripps Research Inst Antibody targeting through a modular recognition domain
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
EP2376099A4 (en) * 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
CA2799608C (en) * 2009-05-28 2023-02-28 Richard H. Weisbart Amino acid sequences which enhance peptide conjugate solubility
WO2011026000A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
EP2712423A4 (en) * 2011-02-25 2015-06-10 Wellstat Diagnostics Llc Assays for detecting enzymatic activity
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
AU2012267492A1 (en) * 2011-06-10 2014-01-09 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
CA2852127C (en) 2011-11-11 2020-10-27 Duke University Combination drug therapy for the treatment of solid tumors
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN104768975A (zh) 2012-08-31 2015-07-08 北卡罗来纳大学教堂山分校 用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CA3120327A1 (en) * 2018-12-06 2020-06-11 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US20230055519A1 (en) * 2020-01-16 2023-02-23 The Translational Genomics Research Institute Methods of identifying synthetic molecular binding agents
WO2022020246A1 (en) * 2020-07-23 2022-01-27 The Scripps Research Institute Insulin receptor-mediated enhancement of gene transfer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
JPH03501487A (ja) * 1988-06-30 1991-04-04 シティ・オブ・ホープ インシュリン模倣物およびインシュリンリセプター結合部位ペプチド
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
DE4432943A1 (de) 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
RU2078769C1 (ru) 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
US5912160A (en) 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
US6028053A (en) * 1995-10-27 2000-02-22 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
AU3568697A (en) 1996-06-07 1998-01-05 Genetics Institute Inc. Polynucleotides from human adult pbmc endocing secreted proteins
ES2242995T3 (es) * 1997-01-15 2005-11-16 Telik, Inc. Moduladores de la actividad del receptor de la insulina.
EP1034188B1 (en) 1997-11-27 2006-06-07 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor (1-462)
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
JP2004512010A (ja) * 2000-03-29 2004-04-22 ディージーアイ・バイオテクノロジーズ・エル・エル・シー インスリン及びｉｇｆ−１受容体のアゴニスト及びアンタゴニスト

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6010017698, Ｊ． Ａｍ． Ｓｏｃ． Ｎｅｐｈｒｏｌ． （２０００） ｖｏｌ．１１， ｎｏ．１１， ｐ．２０２７−２０３５ *
JPN6010017699, Ｂｉｏｐｏｌｙｍｅｒｓ （２０００） ｖｏｌ．５５， ｎｏ．４， ｐ．３４７−３５６ *
JPN6010017701, ＥＭＢＯ Ｊ． （２０００） ｖｏｌ．１９， ｎｏ．７， ｐ．１５２５−１５３３ *
JPN6010017704, Ｇｅｎｅ （１９９３） ｖｏｌ．１２８， ｎｏ．１， ｐ．３７−４２ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501664A (ja) * 2015-10-23 2019-01-24 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用
JP7174627B2 (ja) 2015-10-23 2022-11-17 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用

Also Published As

Publication number Publication date
AU2002341834A1 (en) 2003-04-07
WO2003070747A2 (en) 2003-08-28
AU2002366384A8 (en) 2003-09-09
EP1432433A2 (en) 2004-06-30
CA2459999A1 (en) 2003-04-03
EP1432433A4 (en) 2006-08-30
US6875741B2 (en) 2005-04-05
WO2003027246A3 (en) 2003-07-31
JP2005517741A (ja) 2005-06-16
WO2003027246A2 (en) 2003-04-03
AU2002366384A1 (en) 2003-09-09
EP1496935A2 (en) 2005-01-19
WO2003070747A3 (en) 2004-11-11
EP1496935A4 (en) 2006-06-07
CA2460055A1 (en) 2003-08-28
US20030195147A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
JP2005505579A (ja) アンタゴニスト
US7173005B2 (en) Insulin and IGF-1 receptor agonists and antagonists
US20090192072A1 (en) Insulin and IGF-1 Receptor Agonists and Antagonists
JP3971108B2 (ja) インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
AU2002248609B2 (en) IGF antagonist peptides
JP4467549B2 (ja) インシュリン様成長因子（ｉｇｆ）ｉ変異体
EP1383793B1 (en) Insulin and igf-1 receptor agonists and antagonists
WO2000023469A2 (en) Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
ES2301547T3 (es) Tratamiento de trastornos del cartilago.
JP2001520748A (ja) Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
JP2007537711A (ja) Ｉｇｆ結合タンパク質
J. Mahon The parathyroid hormone receptorsome and the potential for therapeutic intervention
GB2471693A (en) Parathyroid hormone related protein antagonists
WO2001036446A2 (en) Use of g-protein coupled receptors (gpcrs) and modified gpcrs for the treatment of diseases
US7148193B2 (en) Compounds that bind to growth hormone receptor
Bathgate et al. Relaxin family peptide receptors in GtoPdb v. 2021.3
CA2403788A1 (en) Receptor-binding compounds and methods for identifying them
AU2007202546A1 (en) IGF antagonist peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100917

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110125